Tag:
GlaxoSmithKline
Latest Headlines
Latest Headlines
Reuters: Drugmakers crafting emergency plan for Greece
Drugmakers are putting together a plan for how to keep medications flowing to Greece if the economy collapses and payments become uncertain.
HGS puts 'poison pill' in its arsenal against GSK
Human Genome Sciences has added a poison pill to its portfolio as it tries to fend off the hostile takeover by its longtime partner GlaxoSmithKline.
HGS faces skeptics as it boasts of a crowded bargaining table
Human Genome Sciences has prescribed a poison pill for GlaxoSmithKline's hostile takeover bid.
GSK lands one-two punch in melanoma trial
Data from the small mid-stage trial provide early evidence that GSK's two-drug combo could have an edge over Roche's approved melanoma drug Zelboraf.
Cancer drug experts brace for ASCO abstract dump tonight
ASCO is releasing a mountain of data on cancer studies, and some of the biggest names in the business will be angling for star billing on some closely watched therapies.
GSK snags proteomics platform tech in $98M Cellzome buyout
GSK has opted to buy out the company for $98 million, snagging full rights to a pair of early-stage inflammation programs and a proteomics technology.
OncoMed offers $115M IPO bet on cancer stem cell work
A year after scoring a $20 million milestone from Bayer, OncoMed Pharmaceuticals is preparing to see if it can generate enough excitement from investors for its cancer stem cell work to support a $115 million IPO.
Indian gov't probes drug regulator after scathing review
Days after a parliamentary report noted shoddy oversight of approvals, the Indian government has mounted an investigation into the alleged misdeeds. Meanwhile, big names in biopharma have surfaced in the sea of allegations.
India's drug regulator says it will clean up its act
India's health agency has vowed that its top drug regulator will clean up its act, saying it will cinch up oversight rules for letting drugs on the market.
Google's Brin allies with Pfizer and GSK in war on Parkinson's
Brin has put some serious dollars behind the R&D efforts, spending $132 million so far to fund programs through the Michael J. Fox Foundation and discovery work at pharma giants Pfizer and GlaxoSmithKline, Bloomberg reports.
